<DOC>
	<DOCNO>NCT02945657</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic parameter safety topical MM36 ( OPA-15406 ) ointment pediatric subject atopic dermatitis maximal use condition .</brief_summary>
	<brief_title>Pharmacokinetics Safety MM36 Topical Ointment Pediatric Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>This multi-center , open-label study ass degree systemic exposure safety MM36 1 % ointment follow 4 week twice daily dose maximal-use condition pediatric subject atopic dermatitis .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subjects 2 &lt; 18 year age Diagnosis atopic dermatitis ( AD ) AD affect ≥ 35 % BSA 2 &lt; 12 year age ≥ 25 % subject ≥ 12 year age ( exclude scalp venous access area ) Active acute viral skin infection History recurrent bacterial infection Malignancy Clinically significant history physical finding may pose health risk subject may impact study assessment</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>